Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh really? Please share the results of the poll that would confirm your statement.
Oh wait, there is no poll.
EASILY DEBUNKED
I have challenged the pitiful FOOL to a debate on science and he is too chicken to respond, for good reason: HE HAS ZERO SCIENTIFIC BACKGROUND!
HAHAHAHA
Right you are, I had 5 lawyers review the 10k, and about 95 pre-school children, and all agree this is standard boilerplate language.
NASDAQ ON THE WAY
Is this your opinion or did you hear something concrete?
Hahahaahahaahahaahahahahahahahaahababaaba aabababaabaahHahaahahwhwhejejdje
Nicole Saphier, MD
@NBSaphierMD
·
42m
Will tonight’s presser go a step further and discuss monoclonal Ab treatment Leronlimab? Stay tuned.
https://twitter.com/nbsaphiermd/status/1297612963256446977?s=21
Does anyone know if she is credible?
Actually, nothing wrong, reread the post. I said $59.95 for CYDY. If we get there in 2020, I’ll be happy I was wrong, but I’m confident we will reach this price in 2021.
CYDY vs HGEN predictions
HGEN Lenzilumab = nice try, nothing will come from Covid and cancer trials in progress.
CYDY Leronlimab = miracle drug, will start being approved for multiple indications.
HGEN will never see $5.95 again, mark my words!
CYDY $59.95 in 2021!
Leronlimab on JAMAs radar!
Q: Would love to hear updates on leronlimab, lenzilumab, aviptadil, and itolizumab against COVID19.
— JAMA (@JAMA_current) August 20, 2020
A: Question forwarded but not a focus of CDC - all RCTs of investigational treatments at https://t.co/4dLsOvn887 #JAMALive
Please share the poll you took about people caring about RANTES and/or CytoDyn.
Prediction:DEBUNKED
Great news...NOT
How’s the pump n dump strategy going over here? You guys making millions yet?
I would trust the CPA firm if someone could provide the actual valuation report. Without knowing the CPA firm's methodology in determining values, I don't see why I should rely on it as an investor, given that a) the current market cap is a spec of dust compared to the valuation report b) the company doesn't do a good job of laying out their current and future plans and vision that would tangibly lead to such a market cap. As others have stated, the clinical trial stuff for their cancer drug is just copy/paste year to year. You need millions of dollars to fund clinical trials. You can have the miracle drug of the century on your hands, but without $$, your miracle will gather dust on a shelf for decades.
I want nothing more than for this stock to go up so I can make money. At the same time, I feel like the magnitude of pump this stock gets on here does not equate to the reality of the situation.
Yeah, the link is that both company names contain the same initials to form the same acronym. "S"mith "B"arney "F"und "M"anagement = SBFM, hence the 'link'.
Again, I want the company to succeed. But quite frankly, these hyperbolic claims with no backing work against the company imo. Investors care more about how good you are at commercializing your science than ridiculous claims about world rankings and best professor or what not. Please post the results of the competition Slilaty entered and was ranked #5 in the world. If you can’t, then the claim is just meaningless pump fluff.
Agree. As I said in my last post, tiny biotechs develop and market. These guys may be good at developing, but they suck at marketing. Reportedly, $1 billion market cap on paper. Not seeing it yet.
I have my doubts about certain aspects of this company, but the fact they have “no workers or lab” shouldn’t be perceived as a barrier to success. Many promising biotechs start out that way; they develop and market a drug and outsource all the rest. As an example, Humanigen has 3 employees and are currently partnered with Gilead on a cancer trial.
I already own this stock, but bought a few weeks ago during the sharp incline in price, so now I'm doing some extra DD to figure out how to manage my position moving forward.
I want to believe in this company and do think the science is legit. My main concerns are with how successful the company can be at commercializing their science. That's why I wanted to know how MNP valued the company. I assume it's on the future revenue generating potential and/or future buyout value of their patented compounds.
Another thing that crossed my mind is if this is a billion dollar company in disguise, why can't they get the funding needed to accelerate their plans for clinical trials? If I thought my company was worth 100x its current market cap, I would be using the hell out of that report as a marketing tool to draw investors.
Are you sure it was an Indian accent? I'm 99% sure Mr. Sebaaly is of Lebanese background. 100% sure with Dr. Slilaty.
I’m honestly not trying to bash the stock, but without public access to the valuation report, the value claim is meaningless to me as an investor and clearly to the market at large at this point. As an accountant, I want to be able to assess the legitimacy of such a claim by reviewing the numbers and accompanying methodology.
Thanks but this isn’t the actual valuation report. Has that ever been published?
Is this report publicly available? I’d like to know how they calculated valuation. Thanks.
From the site itself: "Access to this database is provided as a public service and shall not be construed as an endorsement or recommendation of the persons or businesses included in the database, nor is it necessarily to be construed as adverse information about persons not included in the database.
The guy's an old fart that got his CPA in the early 80's. He worked at Deloitte, the Big 4, and they require a CPA! Also, I trust the vetting process of a NYSE company over any anonymous internet poster.
Much Ado About Nothing it seems! My fingers are sore from all the DEBUNKING tonight.
He is an inactive CPA, let's burn him at the stake! He has no need to keep his CPA license active in his current role. Given that he's passed the CPA test and was the former CFO of Nautilus, Inc., a NYSE company, I still trust his opinion over any anonymous message board member.
YIPPPPYYYYY!
The excitement is building for sure! I've been long this stock for a while on the advice of my sister (former Harvard professor of medicine and currently medical director of clinical trials at a major pharma company) and my brother in law (phd in Biosciences and masters in finance from Harvard).
Yup, I know, fancy right? But at the end of the day, I trust their opinion over any anonymous internet poster and they believe in the science. I also have a contact at UCLA that has administered Leronlimab and all I can safely say here is his feedback is positive.
Yes, I love to hear this!!! ATTENTION ALL SHORTS: please sell your shares very cheaply to me and my fellow CYDY longs. We appreciate your hospitality.
Well, I guess we'll have to see what happens. The Board disagrees with you. Personally, I will trust the opinion of their CFO, who is a CPA, over an anonymous message board member.
Nothing is DEBUNKED until they apply and get rejected. If that happens, I will eat crow.
GOOD NEWS folks. CytoDyn has passed Nasdaq's board independence test! Four out of six board members are independent!
Uplist here we come!!!
Dr. Welch is a consultant to the company.
From the Annual Report:
""Director Independence
In determining director independence, we use the definition of independence in Rules 5605(a)(2) and 5605(c)(2) of the listing standards of The Nasdaq Stock Market (the “NASDAQ Rules”).
The Board has determined that Messrs. Naydenov, Klump and Dockery and Dr. Welch are currently independent under the NASDAQ Rules in that each is not, and has not been, an executive officer or employee and does not otherwise have a relationship which, in the opinion of the Board, would interfere with his exercise of independent judgment in carrying out the responsibilities of a director.""
So Welch, plus Timmins and Patel, (who I have no reason to believe are not independent), and Naydenov makes 4 independent directors. The annual report goes on to discuss that Dr. Welch is not independent with respect to sitting on the audit committee but that's not relevant because he doesn't sit on the audit committee.
""Also on July 15, 2019, we entered into a consulting agreement with Dr. Welch which named Dr. Welch to the non-executive position of Strategy Advisor, with compensation of $20,000 in cash per month payable in arrears and the grant of a stock option to be determined by the Board, which are in addition to any fees that Dr. Welch currently earns as a director. We expect to evaluate the term of the agreement on a month-to-month basis. The agreement contains customary confidentiality and indemnification provisions and was approved by the Board.""
Well yes, in fact they do...4 out of 6 board members are now independent. 4 out of 6 constitutes a majority of 66.6% independence.
NP is a god amongst men. He is the reincarnation of Darius the Great.
The science is positive so nothing left but to descend into ad hominem attacks, the last line of defense.
LOL We call this “CYA” in the professional business world. No serious businessperson or investor will blink an eye at a disclaimer ROLMFAO
NOPE not broke any more!
I don’t expect $75 on Friday either but consider that MRNA has over $30b market cap with zero approved drugs and no full trial results. Moderna insiders have been selling shares under the radar fast and furious during the COVID-19 run up as well, enriching themselves far beyond anything NP has done at CYDY.
I think it’s a stretch to compare a legendary company like Kodak that has a legion of political and financial connections cultivated over the past century with little ol' CytoDyn when referencing shareholder interest and insider chatter.
Kodak may have declined in revenues, but the name & recognition of the brand is still widely known.
Apples and Oranges. You can't compare a legendary company like Kodak that has a legion of political and financial connections cultivated over the past century with little ol' CytoDyn when referencing shareholder interest and insider chatter.
Kodak may have declined in revenues, but the name & recognition of the brand is still widely known.
And the immoral of the story is "don't ever sell OTC penny stock on no bad news"
Big institutional investors don't have their claws in this yet so it's not like they have access to news we don't, in case anyone's wondering about that causing the price drop. No bad news; no true 'whale' interest....So that leaves only one reason for the stock plunging this week (see original post)
Trading 000